- PLN363.44m
- PLN518.45m
- PLN370.57m
Brief: Selvita Appoints Rafal Chwast As CEO
Brief: Selvita Q2 Net Loss At 3.0 Mln Zlotys
Brief: Selvita Receives Significant Order From European Biopharmaceutical Company Worth Up to €5 Million
Brief: Selvita Q1 Net Loss At 5.5 Million Zlotys
Brief: Selvita May Consider Delisting Under Strategic Options Review
Brief: Selvita Receives EUR 1.3 Mln Order From European Biopharmaceutical Company
Brief: Selvita Estimates Q1 Consolidated Operating Revenue At 78-82 Mln Zlotys
Brief: Selvita FY Net Profit At 0.8 Million Zlotys
Brief: Selvita Unit Receives EUR 3.3 Mln Order For Drug Analytical Work
Brief: Selvita's Unit Receives Purchase Order For 1.6 Mln GBP
Brief: Selvita Reports Growing Sales In Q2 And Q3, And Projects Increased Profitability In H2 2024
Brief: Selvita's Unit Signs $2.1 Mln Deal With US Biotechnology Company
Brief: Selvita Finalizes Acquisition Of Pozlab
Brief: Selvita FY Net Profit Up At 69.9 Mln Zlotys
Brief: Selvita To Acquire 100% Of Stake In PozLab For 25.0 Mln Zlotys
Brief: Selvita Gets Significant Purchase Order
Brief: Selvita To Expand Its Operations Through New Biological Drug Business
Brief: Selvita Q3 Net Result Turns To Net Loss Of 4.3 Mln Zlotys
Brief: Selvita Q2 Net Profit Up At 7.9 Mln Zlotys